Roche Germany A.I CyberSecurity Scoring
01/02/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Roche Germany in 2026.
No incidents recorded for Roche Germany in 2026.
No incidents recorded for Roche Germany in 2026.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Latest updates, reports, and threat intel affecting the global network.
Five pharma cybersecurity breaches to know and learn from. The transition to digital, expedited by the Covid-19 pandemic, has opened up new cybersecurity...
Huawei has been used by the discredited Trump administration as a pawn in a geopolitical game, says former Irish Minister.
The unit has seen eight new partners added to its partnership in FY20: Alex Moreno, Barbara-Anne Bensted, Damian Armour, David Kelly, Jennifer Roche, Scott...
Roche has confirmed that it experienced a cyber-attack, after being named in a German public radio report. The cyber-attack used malware...
German blue-chip companies BASF, Siemens, Henkel along with a host of others said on Wednesday they had been victims of cyber...
Roche has acknowledged it, like Bayer, was target of a cyberattack known as Winnti, which experts say appeared to be launched by Chinese hackers.
LibreChat is an enhanced ChatGPT clone that supports multiple AI providers. In versions up to and including 0.8.3, a shared-agent editor can delete file records through `DELETE /api/files` that the owner has reused across multiple agents. The deletion removes the file globally — not just from the shared agent — breaking the owner's other private agents that reference the same `file_id`. The private agent retains a stale `file_id` reference that no longer resolves. A shared-agent editor can destroy files that the owner uses across multiple agents. The owner's private agents — which the attacker has no access to — break silently with stale `file_id` references. This is a cross-agent integrity violation: editing access to one agent should not affect another. Version 0.8.4 contains a patch.
LibreChat is an enhanced ChatGPT clone that supports multiple AI providers. In versions up to and including 0.8.3, users with only `VIEW` access to an MCP server can retrieve the server's decrypted admin-managed secrets through `GET /api/mcp/servers` and `GET /api/mcp/servers/:serverName`. The returned config includes plaintext values for `apiKey.key` and `oauth.client_secret`. This allows viewers of a shared MCP server to exfiltrate the underlying provider credentials. Version 0.8..4 contains a patch. Other remediations include: never returning decrypted admin-managed secrets to non-owners; redacting apiKey.key and oauth.client_secret from all API responses consider returning only boolean presence indicators for secrets, similar to the auth-values route pattern; and, if owners need to edit configs without re-entering secrets, preserving secrets server-side and returning placeholders instead of plaintext.
When returning errors, functions in the net/textproto package would include its input as part of the error. This might allow an attacker to inject misleading content to errors that are printed or logged.
Decoding a maliciously-crafted MIME header containing many invalid encoded-words can consume excessive CPU.
alf.io is an open source ticket reservation system for conferences, trade shows, workshops, and meetups. Prior to version 2.0-M5-2606, the alf.io extension sandbox injects a fully-functional HTTP client (`simpleHttpClient`) into every extension script's scope. The `postFileAndSaveResponse()` method accepts an arbitrary filesystem path as its `file` parameter and reads the file contents using `new FileInputStream(file)` with no path validation, directory restriction, or allowlist. A malicious extension script can read any file accessible to the JVM process user and exfiltrate it to an attacker-controlled server via HTTP POST. Version 2.0-M5-2606 patches the issue.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.